During the last decade lung cancer has become the major cause of death from cancer in Western countries. The treatment of choice remains surgery when the disease is operable. In fact, adjuvant treatments including chemotherapy and radiotherapy have been extensively used, but no definitive conclusions have been reached about their effectiveness (Le Chevalier et al., 1991; Marino et al., 1994) . In particular, combined therapies have not unequivocally proved to be superior to a single treatment modality, i.e. surgery in operable locally advanced stages II and i11a tumours (Martini and Flehinger, 1987; Naruke et al., 1988) .
The identification of biological markers to complement clinicopathological findings for a more accurate definition of individual patients prognosis and to help clinicians in treatment decision-making is therefore of utmost importance. Moreover, it is hoped that, as for some biological factors in other human tumour types (Paradiso et al., 1993; Amadori et al., 1994) , predictors of response to different systemic treatments will also be identified in lung cancer. DNA ploidy, cell proliferation, and products of oncogenes or tumour-suppressor genes in lung cancer have been extensively investigated (Volm et al., 1985; Alama et al., 1990; Isobe et al., 1990; Miyamoto et al., 1991; Silvestrini et al., 1991; Tungekar et al., 1991; Filderman et al., 1992; McLaren et al., 1992; Quinlan et al., 1992; M0rkve et al., 1993; Scagliotti et al., 1993; Ebina et al., 1994; Passlick et al., 1994) . However, consistent results have not been achieved, probably owing to the heterogeneity in terms of stage and treatment in case series analysed, which implies interference of confounding factors.
On a series of patients with operable locally advanced non-small-cell lung cancer (NSCLC), we analysed the role of P53 expression, S-phase cell fraction and DNA ploidy, alone or in association with pathological characteristics, in providing information on relapse-free survival. The slides were examined with an automated image system (Discovery, Becton Dickinson, Leiden, The Netherlands). Thionine-stained nuclei were identified on the slides using a 620 nm filter, and DAB-positive nuclei were detected using a 500 nm filter. Thionine was used because its absorption spectrum does not interfere with the DAB spectrum. The image was segmented into objects and background by interactive thresholding. Objects that were too small (artefacts) or too large (overlapping nuclei) were removed from the counting on the basis of several morphological features, including nuclear area, perimeter, skeleton size and densitometric features. Negative controls were used to establish non-specific background levels, and the positive antibody threshold was defined on the control slide. The measurement was performed on about 5000 total nuclei from different areas for each tumour.
DNA ploidy Nuclei suspensions were prepared from frozen material as described previously (Costa et al., 1992) . The suspensions were stained with a solution containing propidium iodide (50 Mg ml-'), RNAase, (100 kU ml-') and Nonidet P40 (0.05%) for at least 20 min at 4°C. Human normal lymphocytes were used as an internal standard. DNA content was measured with a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA), and a total of 30 000 nuclei was acquired for each sample. DNA ploidy was expressed as DNA index (DI), and the samples were defined 'diploid' when the DI was 1.0, 'aneuploid' when two distinct peaks could be discerned (indicating the presence of an abnormal DNA cell population), or 'multiploid' when more than one abnormal stemline was present.
Statistical analysis
The free-distribution Kolmogorov-Smirnov test was used to compare the distributions of P53 expression and [3H] dT LI values between DNA ploidy subsets, as well as between stage and histology groups. The relationship between P53 expression and [3H]dT LI values was assessed by Spearman's correlation coefficient, and the association between P53 expression and DNA ploidy, as well as between such biomarkers and pathological characteristics was investigated by the logistic regression model. In this model, each regression coefficient is the logarithm of an odds ratio, and under the null hypothesis of no association, the odds ratio is expected to be 1.00.
Relapse-free survival was computed starting from the date of surgery, and the median follow-up was 20 months (range, 1-71 months). New disease manifestation (local recurrence (Figure 1) .
When the biological and pathological variables were singly considered for the overall series, the only significant indicator of relapse-free survival during the observation period was pathological stage (Table II Figure 2. [3H]dT LI showed a significant prognostic relevance in patients with adenocarcinoma (HR = 1.07, 95% CL= 1.01-1.44; P= 0.027) but not in patients with squamous cell carcinoma (HR=0.99; P=0.56). In fact, for both histologies the prognosis of stage IIa patients was worse than that of stage II patients. However, in adenocarcinoma patients, a statistically significant inverse relation was also observed between relapse-free survival probability and [3H] dT LI values within each pathological stage. Conversely, in squamous cell carcinoma patients, the prognosis was not influenced by cell proliferation.
For clinical purposes, the most prognostic discriminant [3H]dT LI cut-off was investigated in adenocarcinoma ( Figure  3) . The values of 4% and 3% respectively for stage II and Ila identified two subgroups of patients at different risk of relapse within each stage, with the maximum discriminant power in stage MIIa (rapidly vs slowly proliferating tumours: HR = 8.2, 95% CL = 2.8 -24.1; P = 0.0001).
Discussion
Our results showed that P53 expression, DNA ploidy and [3H]dT LI were unrelated biological variables in locally advanced operable squamous cell and adenocarcinomas of 100 Biomarkers in operable stage 11 and Ilia NSCLC A Costa et at 917 the lung. In particular, the independence of P53 expression and cell proliferation, as observed for other tumour types (Silvestrini et al., 1993; Costa et al., 1995) , supports the hypothesis that P53 has other biological functions in addition to cell -cycle regulation. Moreover, except for a relation between cell proliferation and histology, such biological variables were independent of pathological characteristics, in agreement with previous data (Kerr et al., 1983; Alama et al., 1990; Isobe et al., 1990; Miyamoto et al., 1991; Silvestrini et al., 1991; Filderman et al., 1992; Quinlan et al., 1992; M0rkve et al., 1993; Scagliotti et al., 1993; Ebina et al., 1994; Passlick et al., 1994) .
P53 expression of human lung cancer has been determined immunohistochemically on frozen (McLaren et al., 1992; Passlick et al., 1994) or routinely processed paraffinembedded sections (Quinlan et al., 1992; Ebina et al., 1994) . McLaren et al. (1992) showed no correlation between (1994) showed that P53 expression detected on paraffin-embedded tissue was an independent predictor of a short survival in a subset of curable patients with P53 negative-or more than 10% P53-positive tumour cells. Such conflicting results can be ascribed to heterogeneity in methodological approaches and case series. In particular, artefacts could be due to a long-term fixation and fixation gradient, or to uneven distribution of the antibodies. Moreover, criteria for patient inclusion were not reported in some studies, and selected series were probably analysed. Our results in a consecutive series of patients failed to evidence a prognostic role of P53 expression in operable, locally advanced NSCLC.
Several studies have attempted to define the prognostic role of DNA ploidy in patients with all NSCLC histologies and at all stages (Volm et al., 1985; Isobe et al., 1990; Miyamoto et al., 1991; Filderman et al., 1992; M0rkve et al., 1993) . Most studies have shown a worse prognosis for patients with aneuploid than for those with diploid tumours (Volm et al., 1985; Isobe et al., 1990; Miyamoto et al., 1991; Filderman et al., 1992) , but contrasting results are not lacking (Cibas et al., 1989; M0rkve et al., 1993) . In the present study, DNA abnormalities were observed in a very high percentage of tumours (about 90%), and the prognosis was slightly worse for patients with mutliploid tumours than for those with diploid tumours, even though the difference was not statistically significant.
The rate of tumour cell proliferation has proved to be a prognostic factor in several tumour types (Silvestrini, 1994) . In particular, [3H]dT LI, an indicator of the fraction of cells actively synthesising DNA, has been demonstrated to be a predictor of prognosis in stage I NSCLC (Alama et al., 1990; Silvestrini et al., 1991) . In the present study on stage II-IIIa NSCLC, we showed that [3H]dT LI has an additive prognostic role in adenocarcinomas but not in squamous cell carcinomas. Such a finding suggests that in patients with a favourable histology and operable, locally advanced disease the biological variables give no prognostic information.
In conclusion, analysis of the clinical relevance of some biological factors in advanced lung cancer has shown that multiclonality is a weak indicator of risk, whereas the S-phase cell fraction provides independent information additive to that given by stage, which remains the most important factor in squamous cell carcinoma. The failure of P53 expression to give prognostic information could indicate that the marker plays a role in the initiation of tumour malignancy but is of minor importance in tumour progression.
